
    
      A 12-Week, Exploratory, Open-Label, Nonrandomized, Dose-Escalation Study of the Efficacy,
      Safety and Tolerability of Oral CEP-701 in Patients with Severe, Recalcitrant, Plaque Type
      Psoriasis.
    
  